

Index

Note: Page references in *italics* refer to Figures; those in **bold** refer to Tables.

- ABMR. *see* antibody-mediated rejection (ABMR)
- ABO blood groups, 287–8, **287**
- Academy of Medical Royal Colleges, 301
- acetate
 - electrolytes in, 193
 - in HD prescription, 192, 193, 193
- Achinger, S.G., 190
- acidaemia, 40–1
- acid–base balance
 - in stage 4 CKD
 - control of, 139–40
- acid–base control, 39
- acid–base fluctuations
 - in healthy persons
 - renal processes in correcting, 40–1, **42**
- acidosis, 40–1
 - dietary management of, 377
 - metabolic *see* metabolic acidosis
- ACR. *see* albumin: creatinine ratio (ACR)
- Acuna, S.A., 279
- Acute Dialysis Quality Initiative (ADQI), 112
- acute interstitial nephritis
 - AKI related to, 109–10
- acute kidney injury (AKI), 105–25
 - acute IDH in, 118
 - causes of
 - acute interstitial nephritis, 109–10
 - acute liver injury, 110
 - ATN, 111
 - cortical necrosis, 110
 - identification of, 113
 - nephrotoxicity, 111, **111**
 - postrenal failure, 112
 - prerenal renal failure, 107–8, *109*
 - renal failure, **108**, 109, 110
 - rhabdomyolysis, 110
 - in children, 361–3 *see also* children, AKI in
 - CKD and, 105
 - classification of, 107, **108**
 - classification systems for, 112–13, **113**, **112**
 - clinical course of, 117–18, **117**
 - costs related to, 105
 - CRRT in, 107, 119–23, *120–2*, 362–3
 - hyperkalaemia and, 114
 - IHDF in, 118–19
 - introduction, 105–13, *106*, *108*, **109**, **111–13**
 - management of, 114–17
 - hyperkalaemia-related, 114
 - infection-related, 116
 - metabolic acidosis-related, 115
 - nutrition in, 115–16
 - sepsis-related, 116–17
 - uraemia-related, 115
 - urological obstruction-related, 114
 - volume overload-related, 115
 - mortality related to, 107
 - NCEPOD on, 105
 - NICE on, 105–6, 113
 - prevention of, 114
 - RRT for, 106, 118–23, *120–2*
 - in children, 362–3
 - signs and symptoms of, *106*, *107*
 - stages of, 117–18, **117**
- Acute Kidney Injury Network (AKIN), 112, **112**
- acute liver injury
 - AKI related to, 110
- acute peritoneal dialysis (PD)
 - in AKI, 121
- acute rejection, 322, 323
 - after renal transplantation, 326
- acute tubular necrosis (ATN), 300
 - after renal transplantation, 326
 - AKI related to, 111
- adenosine triphosphate (ATP), 30
- ADH. *see* antidiuretic hormone (ADH)
- adolescence
 - renal disease during
 - transition to adult services, 363–4
- ADPKD. *see* autosomal dominant polycystic kidney disease (ADPKD)
- ADQI. *see* Acute Dialysis Quality Initiative (ADQI)
- advanced kidney disease (AKD)
 - conditions causing, 43
 - dietary management of, 367–411
 - see also* dietary interventions
 - physical and psychosocial
 - sexual concerns related to, 91–3, **91**
 - renal transplantation for, 395–7
- advance planning
 - in palliative care, 340–1, **341**
- Advisory Committee for European Best Practice Guidelines, 265
- age
 - as factor in renal transplantation, 280, **281**
- air embolism
 - during HD, 222–3, 223–4
- AKD. *see* advanced kidney disease (AKD)
- AKI. *see* acute kidney injury (AKI)
- AKIN. *see* Acute Kidney Injury Network (AKIN)
- alanine aminotransferase (ALT), 155–6
- albumin, 29
 - in AKI, 122
 - in urine, 164
- albumin: creatinine ratio (ACR), 164
- albumin-saline combination
 - in AKI, 123
- aldosterone
 - in fluid volume regulation, 34
 - in potassium content, 36
- ALG,ATG–polyclonal antibodies
 - in immunosuppression
 - induction, 318
- Allen, L., 225–6
- Allis-Chalmers Corporation, 5

- ALT. *see* alanine aminotransferase (ALT)
- altruism
in living relation donation, 302–3
- American Diabetes Association, 49
- American Society for Artificial Internal Organs, 12
- amyloidosis
described, 56
renal, 56–7
- anaemia
dietary management of, 377
investigations for, 158–9
management of
in children with renal disease, 354
in stage 4 CKD
control of, 137
symptoms of, 158–9
“analgesic ladder”
of WHO, 344
- angiogram
renal, 175–6
- annual review transplant clinic (ARTC), 100–1
- AN69 ST membrane, 195
- antibiotics
prophylactic
prior to PD, 244
- antibodies
ALG, ATG–polyclonal
in immunosuppression
induction, 318
T-cell depleting
in immunosuppression
induction, 318
- antibody-mediated rejection (ABMR), 322, 323
- anticoagulation
in HD, 204–7, 207
within extracorporeal circuit, 205–6
HIT related to, 206–7
- antidiuretic hormone (ADH), 26
in fluid volume regulation, 33, 34
- antigen(s)
histocompatibility, 288
human leukocyte, 288–9, 289
transplant, 286
- antilymphocyte globulin (ALG), antithymocyte globulin (ATG)–polyclonal antibodies
in immunosuppression
induction, 318
- antiproliferative agents
in maintenance immunosuppression, 319–20
- anxiety
pre-renal transplant–related, 283–4
- APD. *see* automated peritoneal dialysis (APD)
- aPD. *see* assisted peritoneal dialysis (aPD)
- Appel, K., 8
- area puncture
in AVF and AVG function
preservation, 214, 216
- arm
veins of, 149, 149
- ARPKD. *see* autosomal recessive polycystic kidney disease (ARPKD)
- ARTC. *see* annual review transplant clinic (ARTC)
- arteriosclerosis
diabetes mellitus and, 49
- arteriovenous fistula (AVF), 87
for HD, 208, 208, 209
in vascular access
cannulation techniques, 213–18, 214–16
care of, 213
- arteriovenous graft (AVG), 87
for HD, 208, 209–10, 209
in vascular access
cannulation techniques, 213–18, 214–16
care of, 213
- artificial kidney
history of, 2
- Ashby, D., 94
- aspartate aminotransferase (AST), 155–6
- ASSIST-CKD project, 132
- assisted peritoneal dialysis (aPD), 86
- AST. *see* aspartate aminotransferase (AST)
- ATN. *see* acute tubular necrosis (ATN)
- atorvastatin
for CKD, 155
- ATP. *see* adenosine triphosphate (ATP)
- atrial natriuretic peptide
in fluid volume regulation, 34
- Austin Diagnostic Clinic, 12
- automated peritoneal dialysis (APD), 86, 249, 252
history of, 13
peritonitis resulting from
obtaining effluent specimen, 267–8
- autosomal dominant polycystic kidney disease (ADPKD), 54
- autosomal recessive polycystic kidney disease (ARPKD), 54
- AVF. *see* arteriovenous fistula (AVF)
- AVG. *see* arteriovenous graft (AVG)
- azathioprine
in maintenance immunosuppression, 319–20
- bacterial infections
after renal transplantation, 327
- Baker, R., 92
- Ball, L., 218
- BAPEN. *see* British Association for Parenteral and Enteral Nutrition (BAPEN)
- Barlow, A.D., 331
- Bartter's syndrome, 352
- basiliximab
in immunosuppression induction, 317–18
- basophil(s)
in WBC count, 158
- basophilia, 158
- baths
in dialysis history, 1
- BBV. *see* blood-borne virus (BBV)
- BCOP. *see* blood colloid osmotic pressure (BCOP)
- BCSE. *see* Brief Cognitive State Examination (BCSE)
- BDA. *see* British Dietetic Association (BDA)
- Beck Depression Inventory, 90
- behaviour change
transtheoretical model of, 95, 95
- belatacept
in maintenance
immunosuppression, 321
- Belzer, 15
- Bence Jones protein
in urine, 164
- “Better Care in My Hands,” 60
- BFR. *see* blood flow rate (BFR)
- bicarbonate
in HD prescription, 192, 193–4, 193
in renal profile, 154
- bicarbonate buffering system, 39–40
- bicarbonate ions
renal processes in control of, 40, 41
- bicarbonate/lactate-based solutions
in PD, 255–7
- bilateral nephrectomy
technique, 299–300, 300
- bilirubin
in renal profile, 156
- biochemical blood tests, 150–65
bicarbonate, 154
calcitriol, 154
calcium, 151, 153
Coombs' test, 161
creatinine, 151, 152
CRP, 160–1

- FOBT, 161
 glucose, 154
 glycosylated haemoglobin, 154–5
 haematological tests, 156–8, 157
 haptoglobins, 161
 LDH, 161
 LFTs, 155–6
 lipids, 155
 occult blood, 161
 phosphate, 151, 153–4
 potassium, 151, 152–3
 PTH, 154
 in renal profile, 151–4, 151
 reticulocytes, 161–2
 serum protein electrophoresis, 155
 sodium, 151, 152
 urea, 151–2, 151
 uric acid, 154
 WBC count and differential, 157, 158–60
- biopsy
 kidney, 168–71 *see also* kidney biopsy
 transplant, 322–3
 BK (polyoma) virus
 after renal transplantation, 328
 bloodspot
 RPSG on, 71, 73
 blood
 occult
 in renal profile, 161
 in urine, 163
 blood-borne virus (BBV)
 occupational exposures to, 148
 blood clotting
 calcium ions in, 38
 blood colloid osmotic pressure (BCOP), 28–9
 blood flow rate (BFR)
 in improving HD clearance, 196–7
 blood glucose
 control of
 in diabetes patients on PD, 252–3
 blood pressure
 management of
 in children with renal disease, 353–4, 354
 blood pressure–renal function
 relationship
 renal processes in, 42–3
 blood sample
 normal
 analysis of, 150–1, 151
 blood-stained effluent
 in PD, 264
 blood supply
 during PD, 238
 blood transfusions
 in renal transplantation
 history of, 16
- blood volume calculation
 in HD
 in children, 360, 360
 blood volume monitoring
 in HD prescription, 204
 BMI. *see* body mass index (BMI)
 body composition
 assessment of
 hypoalbuminaemia, 390–1
 malnutrition-related, 392
 PEW in, 391
 renal-specific formulae, 394–5
 SGA in, 391
 techniques, 390–5
 changes in
 malnutrition and, 378–9
 body fluid volume
 renal processes in regulation of, 33–4, 34
 body mass index (BMI)
 in body composition
 assessment, 390
 calculation of, 405
 body osmolality, 26, 26
 Boen, S.T., 11
 bone density scan
 in renal assessment, 171
 bone disease
 after renal transplantation, 397
 in stage 4 CKD
 management of, 137
 bone health
 management of
 in children with renal disease, 354–5
 Booth, J., 204
 Borzou, S.R., 197
 Bossola, M., 89–90
 Bowman's capsule, 22, 24
 structure of, 27, 27
 Boyle, Sir R., 7
 brain stem
 functions of, 292
 brain stem death
 causes of, 291, 291
 declaration of, 292
 diagnosis of, 292
 time of, 292
 Bray, B.D., 221
 Brescia, M., 8
 Brief Cognitive State Examination (BCSE), 98
 British Association for Parenteral and Enteral Nutrition (BAPEN), 388
 British Dietetic Association (BDA), 392
 Renal Nutrition Group of, 369
 British Hypertension Society, 353
 British Medical Association, 312–13
- British Royal Society, 221
 Vascular Access Special Interest Group of, 211, 215, 216
 British Transplant Society, 306
 BRVASIG. *see* British Royal Society Vascular Access Special Interest Group of
- Burns, T., 96
 buttonhole technique
 in AVF and AVG function
 preservation, 214–15, 215, 214
 Byrne, C., 294
- CAI. *see* chronic allograft injury (CAI)
 calcineurin inhibitors
 in maintenance
 immunosuppression, 318–19
 calcitonin
 in phosphate and calcium control, 38, 39
 calcitriol
 in renal profile, 154
 calcium
 in acetate, 193
 metabolism of
 dietary management of, 374
 PTH in control of, 31
 renal processes in regulation of, 36–8, 38, 39
 in renal profile, 151, 153
 calcium ions
 in blood clotting, 38
 in regulation of nerve and muscle functions, 38
 calcium resonium, 377
 Campbell-Crofts, S., 85
 Canada-USA (CANUSA) Peritoneal Dialysis Study Group, 388, 391
 Canadian Society of Nephrology, 84
 cannulation techniques
 in AVF and AVG function
 preservation, 213–18, 214–16
 area puncture, 214, 216
 buttonhole technique, 214–15, 215, 214
 correct needle placement in, 217
 by experienced and well-trained nurses, 218
 gentleness and sensitivity in, 217
 planning of, 217
 procedure guidelines, 216–18
 rope ladder technique, 214, 215–16, 216
 self-awareness of cannulator in, 217
 tourniquet use in, 218

- CANUSA Peritoneal Dialysis Study Group, 388
- CAPD. *see* continuous ambulatory peritoneal dialysis (CAPD)
- capillary endothelium, 237, 237
- capillary-flow dialyser, 6
- cardiac disease
- in evaluation for renal transplantation, 281
- cardiovascular disease (CVD)
- after renal transplantation, 396–7
 - as contraindication to renal transplantation, 280
 - risk factors for
 - dietary interventions, 372–3
- cardiovascular problems
- in PD, 262–3
- cardiovascular risk management
- in stage 3a–3b CKD, 134–5
- Care Quality Commission, 60
- carer involvement
- in renal nursing care, 59–74
 - case study, 66–9
 - in renal nursing education, 74–6
 - in renal research, 77–8, 77
- CARI. *see* Caring for Australians with Renal Impairment (CARI)
- Caring for Australians with Renal Impairment (CARI), 373, 377
- Carrel, A., 14
- Casey, J.R., 226–7
- cast(s)
- in urine, 165
- Castro, M., 271
- CAT. *see* computed axial tomography (CAT)
- catheter(s). *see also specific types*
- central venous
 - for HD, 208, 210
 - tunnelled *see* tunnelled central venous catheters (TCVCs)
 - care
 - in PD
 - history of, 10–12
 - malpositioned, 264
 - Swan-neck, 243, 243
 - in postoperative care of renal transplant recipients, 325
 - Tenckhoff, 11–12, 243, 244, 243
 - Toronto Western
 - in PD, 243, 243
 - Cavanaugh, K.L., 210
 - CCPD. *see* continuous cyclic peritoneal dialysis (CCPD)
 - central nervous system (CNS) disorders
 - in stage 4 CKD, 140
 - central venous catheters (CVCs)
 - for HD, 208, 210
 - tunnelled *see* tunnelled central venous catheters (TCVCs)
 - care
 - Centre for Epidemiologic Studies Depression Scale, 90
 - Chambers, E.J., 344
 - Chandna, S.M., 340
 - Chen, N.-H., 86
 - childhood. *see also* children
 - physiology in
 - impact on renal care, 350–1, 351
 - renal disease in, 350
 - children. *see also* childhood
 - AKI in, 361–3
 - causes of, 361–2
 - conservative management of, 352–5, 354
 - described, 361
 - treatment of, 362–3
 - atypical HUS in, 363
 - biochemistry reference ranges for, 350, 351
 - CKD in, 351–2, 352, 351
 - conservative management of, 352–5, 354
 - dietary interventions for, 398–9
 - dialysis in, 358–61, 360
 - HD, 359–61, 360 *see also* haemodialysis (HD), in children
 - PD, 358, 359
 - preparation for, 358, 358
 - ERD in, 351, 351
 - fluid balance in, 350
 - growth in, 350
 - HD in, 359–61, 360
 - HUS in, 363
 - immunosuppressed
 - immunisation for, 358
 - NS in, 48, 355–6 *see also* nephrotic syndrome (NS), in children
 - PD in, 358, 359
 - renal anatomy in, 350–1, 351
 - renal care of, 349–66
 - renal disease in, 350
 - renal transplantation for, 356–8, 358
 - care after, 357
 - complications following, 357–8
 - immunosuppression after, 357
 - living donor transplantation, 356–7
 - LRD, 357
 - pre-emptive transplantation, 357
 - preparation for, 358, 358
 - RRT in, 356–8, 358
 - Chionh, C.Y., 121
 - chronic allograft injury (CAI), 323–4
 - chronic kidney disease (CKD), 127–46
 - AKI and, 105
 - atorvastatin for, 155
 - in children, 351–2, 352, 351
 - conservative management of, 352–5, 354
 - dietary interventions for, 398–9
 - presenting symptoms, 351, 352
 - conditions causing
 - conditions causing, 43–57 *see also specific conditions*
 - diabetic kidney disease, 48–9
 - glomerulonephritis, 49–53, 51
 - nephrosclerosis, 45
 - nephrosis, 45–8, 46, 47
 - PKD, 54–6, 55, 56
 - pyelonephritis, 53–4
 - renal artery stenosis, 43–5, 44, 45
 - described, 127–31, 130
 - diabetes mellitus and, 127, 136, 136
 - diagnosis explaining, 133
 - dialysis for
 - initiation of, 142, 144
 - dietary treatment of
 - flow chart for, 370
 - GMS contract for, 131
 - HRQoL effects of, 82
 - infertility and impotence related to, 140
 - introduction, 127
 - KDOQI classification of, 129–31, 130
 - management in primary care
 - clinical guidelines for, 131
 - innovation in, 132
 - mild to moderate
 - management in primary care, 132
 - NS, 45–8, 46, 47
 - PDEPs for, 141–2, 143–4
 - phlebotomy in
 - choice of vein, 149, 150, 149
 - predialysis phase of
 - education in, 140–2, 144
 - prevalence of, 127, 336
 - psychological impacts of, 81–104 *see also* psychological perspectives
 - referral for
 - indicators for, 135, 135
 - Renal Association e-guide for, 132
 - stage 3a–3b, 132–5, 135
 - cardiovascular risk management in, 134–5
 - care and management of, 132–5, 135
 - explaining diagnosis, 133

- medicines review, 135
 - monitoring of, 133
 - referral for, 135, 135
 - self-management of, 133–4
- stage 4, 136–40
 - acid–base balance in, 139–40
 - anaemia control in, 137
 - bone disease management in, 137
 - care and management of, 136–40
 - CNS disorders in, 140
 - control of serum bicarbonate within normal levels in, 136–7
 - dermatological disorders management in, 138
 - gastrointestinal disorders control in, 138
 - nutrition in management of, 136
 - potassium disorders control in, 139
 - sexual function problems in, 140
 - volume disorders control in, 138–9
- stage 5
 - symptoms experienced in, 342–5, 343
- staging of, 129–31, 130
- Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI)
 - creatinine equation, 166
- ciclosporin, 15
- Cimino, J., 8
- circulatory death
 - donation after, 301–2
- City University London
 - KREI at, 75
- CKD. *see* chronic kidney disease (CKD)
- CKD Audit, 127
- CKD γ chromium EDTA GFR
 - in kidney function assessment, 168
- CKD-EPI creatinine equation, 166
- CKD-EPI cystatin C-based e-GFR, 167
- CKD-EPI cystatin C equation, 167
- “CKD through Art” initiative, 74
- Clark, W.R., 194
- Clinical Lead in Organ Donation (CLOD), 311
- Clinical Practice Guideline of KDIGO, 96–101, 100
- CLOD. *see* Clinical Lead in Organ Donation (CLOD)
- clotting
 - in HD
 - management of, 204–7, 207
 - see also* anticoagulation, in HD
- intravascular
 - NS and, 48
- CMV. *see* cytomegalovirus (CMV)
- CNS. *see* central nervous system (CNS)
- coagulation
 - in renal profile, 158–9
- Cohen, L.M., 343
- cold ischaemia
 - in deceased donation, 300–1
- collecting duct
 - histological features of, 30, 31
- collodion, 2
- collodion membranes, 2
- Combes, G., 141
- communication
 - in palliative care
 - family-related, 339
 - patient-related, 338–9, 339
 - team-related, 340
- complement
 - in renal profile, 156
- computed axial tomography (CAT)
 - in renal assessment, 173
- computed tomography (CT)
 - in renal assessment, 173
- Conference of Medical Royal Colleges, 292
- conservative kidney management (nondialytic options)
 - psychological perspectives on, 96
- constipation
 - end-of-life care related to, 344
 - in PD, 263–4
- continuing care
 - in postoperative care of renal transplant recipients, 326
- continuous ambulatory peritoneal dialysis (CAPD), 248, 248–9, 252
 - FDA on, 12
 - history of, 1, 12
 - in-centre haemodialysis with, 86
 - peritonitis resulting from
 - obtaining effluent specimen, 267
 - as portable/wearable equilibrium dialysis, 12
- continuous cycling peritoneal dialysis (CCPD), 249–50, 250
 - history of, 13
- continuous haemodiafiltration (HDF)
 - in AKI, 119, 120
- continuous haemodialysis (HD)
 - in AKI, 119, 121
- continuous haemofiltration (HF)
 - in AKI, 119, 120
- continuous renal replacement therapy (CRRT)
 - for AKI, 107, 119–23, 120–2
 - in children, 362–3
- convection
 - in HD, 185, 186, 187
 - in PD, 239–40
- Coombs’ test
 - in renal profile, 161
- Coping Strategies Index (CSI), 88
- Coping Strategy Inventory–Short Form (CSI-SF), 88
- coroner
 - organ donation permission from, 298
- cortical necrosis
 - AKI related to, 110
- corticosteroids
 - in maintenance immunosuppression, 320–1
- Cove, J., 95
- C-reactive protein (CRP)
 - in renal profile, 160–1
- creatinine kinase
 - in renal profile, 156
- creatinine
 - in PD adequacy assessment, 258
 - in renal profile, 151, 152
- creatinine clearance
 - in kidney function assessment, 167–8
- crescentic glomerulonephritis, 50, 52–3
- Cronin, A., 100
- cross-match
 - pretransplant, 289–90
- CRP. *see* C-reactive protein (CRP)
- CRRT. *see* continuous renal replacement therapy (CRRT)
- Cruz, D.N., 121
- CSI. *see* Coping Strategies Index (CSI)
- CSI-SF. *see* Coping Strategy Inventory–Short Form (CSI-SF)
- CT. *see* computed tomography (CT)
- Cunard, R., 49
- Cuprophane, 5
- CVC(s). *see* central venous catheters (CVCs)
- CVD. *see* cardiovascular disease (CVD)
- cytomegalovirus (CMV)
 - after renal transplantation, 327–8
- Dacron cuff, 11
- Darzi, Lord, 413
- Davenport, A., 205
- Davies, S.J., 271
- Davison, S.N., 346
- DBD. *see* Donation after Brainstem Death (DBD)

- DCCT. *see* Diabetes Control and Complications Trial (DCCT)
- DCD. *see* Donation after Circulatory Death (DCD)
- DCT. *see* distal convoluted tubule (DCT)
- DDS. *see* dialysis disequilibrium syndrome (DDS)
- Dean, N., 11
- deceased donation, 291–302, **291**, **294**, **298**, **300**
- acceptance that death has occurred, 295
 - after circulatory death, 301–2
 - brain stem death
 - causes of, **291**, **291**
 - brain stem functions, 292
 - clinical care of potential organ donor, 297
 - cold ischaemia, 300–1
 - continuing care after donation, 296
 - contraindications to, 292–3
 - DBD *vs.* DCD, 291
 - fear of increasing distress of family, 295
 - how to offer donation, 296
 - organisation of organ donation procedure and surgery, **297**, **298**
 - organ preservation, 300
 - permission from coroner, 298
 - refusal to donate, 296–7
 - religious beliefs, 293–5
 - removal of kidneys from multiorgan donor, 298–9
 - for renal transplant, 291–302, **291**, **294**, **298**, **300**
 - requesting donation, 293
 - SNOD's role, **297**, **298**
 - surgical technique for deceased donor nephrectomy, **299–300**, **300**
 - unconditional gift, 296
 - warm ischaemia, 300
 - when to offer donation, 295
 - who should offer donation, 295
- deceased donation nephrectomy technique, **299–300**, **300**
- decision making
- dialysis-related
 - in palliative care, 340
- definitive access provision
- in vascular access for HD, **210–11**, **212**
- Department of Health, **81**, **311**, **312**, **416**
- depression
- psychological perspectives on, **89–90**
- dermatological disorders
- in stage 4 CKD
 - treatment of, 138
- DEXA scan
- in body composition
 - assessment, 390
 - in renal assessment, 171
- Diabetes Control and Complications Trial (DCCT), 373
- diabetes mellitus
- after renal transplantation, 397
 - CKD and, **127**, **136**, **136**
 - as contraindication to renal transplantation, 280
 - dietary interventions for, **373–4**
 - HD and
 - management of, **224–6**
 - pathologies associated with, 49
 - PD for patients with, **252–4**
 - see also* peritoneal dialysis (PD), for diabetes patients
- Diabetes UK guidelines, **373–4**
- diabetic kidney disease
- CKD due to, **48–9** *see also* diabetic nephropathy
- diabetic nephropathy, **48–9**
- described, 48
 - glucose control and, 49
 - pathology of, **48–9**
- dialysate
- components of, **192–4**, **193**, **192**
 - flow rate of
 - in improving HD clearance, 197
 - in HD prescription, **192–4**, **193**, **192** *see also* haemodialysis (HD) prescription
 - temperature of
 - in HD prescription, **203–4**
- dialysate fluid, **181**, **182**
- dialyser(s). *see also specific types*
- capillary-flow, 6
 - clotting in
 - HD clearance effects of, 198
 - development of
 - history of, **2–9**
 - in HD, **180**, **181**, **182**
 - in HD prescription, **194–5**
 - Kiil, **5**, **6**, **7**
 - Kolff, **3–4**
 - parallel, 6
 - size of
 - in improving HD clearance, 196
- dialysis
- in children, **358–61**, **360** *see also* children, dialysis in
 - for CKD
 - initiation of, **142**, **144**
 - described, 179
 - dietary management during, **382–6**, **383**, **386** *see also* dietary interventions, dialysis-related
 - history of, **1–13** *see also specific types, e.g.*, haemodialysis
 - introduction, 179
 - modality for
 - in HD prescription, **188–92**, **189** *see also* haemodialysis (HD) prescription, dialysis modality
 - nocturnal
 - in HD prescription, 191
 - nutritional health of patient prior to NIH on, 368
 - patient choice for
 - psychological perspectives related to, **86–9**
 - peritoneal *see* peritoneal dialysis (PD)
 - preoperative, 314
 - single-needle *vs.* double-needle
 - in improving HD clearance, 198
 - types of
 - patient choice for, **86–9**
- dialysis decision-making
- in palliative care, 340
- dialysis disequilibrium syndrome (DDS)
- during HD, **222**, **223**
- dialysis modality
- in HD prescription, **188–92**, **189** *see also* haemodialysis (HD) prescription, dialysis modality
- Dialysis Outcome Quality Initiative (DOQI)
- best practice guidelines from, **418–19**
- Dialysis Outcomes and Practice Patterns Study (DOPPS), **88**, **189**, **191**, **208**, **211**, **386**
- Dialysis Outcomes Quality Initiative (DOQI)
- of NKF, 368
- diet(s)
- Giovanetti, 368
 - in management of CKD and AKI
 - in children, **352–3**
 - Mediterranean, 373
 - phosphorus in, 153
 - VLPD, **367–8**
- dietary interventions, **367–411**
- for acidosis, 377
 - for AKD, **367–411**
 - for anaemia, 377
 - calcium-related, 374
 - cardiovascular risk-related, **372–3**
 - for children, **398–9**
 - for CKD
 - flow chart for, 370
 - for diabetes, **373–4**
 - dialysis-related, **382–6**, **383**, **386**
 - current concepts of, **382**, **383**

- energy requirements, 382–3, 383
 historical review, 382
 minerals, 386
 phosphorus, 383, 385
 potassium, 383, 384–5
 protein, 382, 383
 sodium and fluid requirements, 383–4, 383
 vitamin(s), 383, 385–6, 386
 historical review of, 367–9, 369
 for hyperkalaemia, 376–7
 for hyperlipidaemia, 372–3
 for hypertension, 371–2
 for malnutrition, 378–80 *see also* malnutrition
 for NS, 381, 381
 predialysis
 current concepts on, 369–71, 370
 for renal transplant recipients, 397
 for RRT patients, 382, 383
 Dietetic (Nutrition) Care Process, 392
 differential
 of WBC count, 158
 diffuse intercapillary
 glomerulosclerosis
 diabetes mellitus and, 49
 diffusion, 30
 in HD, 184–5, 185, 187
 in PD, 239, 239
 Dijk, P., 254
 Dipstick tests
 in urine evaluation, 163
 distal convoluted tubule (DCT)
 reabsorption in, 30–1, 31
 Dixon, M., 82
 Dobbels, F., 89
 Donation after Brainstem Death (DBD), 291
 Donation after Circulatory Death (DCD), 291
 donor and recipient matching
 in LRD, 305
 for renal transplantation, 286–90, 287, 289 *see also* renal transplantation, donor and recipient matching
 donor organs
 increasing supply of, 310–13, 311
 opting in/opting out, 312–13
 Doolan, P., 10
 Doolan technique, 10
 Doppler studies
 in renal assessment, 174
 DOPPS. *see* Dialysis Outcomes and Practice Patterns Study (DOPPS)
 DOQI. *see* Dialysis Outcome Quality Initiative (DOQI)
- drainage problems
 in PD, 263
 drug(s)
 excretion of, 32
 drug metabolites
 excretion of, 32
 dry weight assessment
 in fluid removal, 199–200, 199
 dual-energy x-ray absorptiometry (DEXA) scan
 in body composition assessment, 390
 in renal assessment, 171
 Dubost, 14
 Dudley, C., 317
- EAPOS. *see* European APD Outcome Study (EAPOS)
 EASE. *see* Encourage Autonomous Self-Enrichment (EASE)
 patient education programme
 East London Community Kidney Service, 132
 “Eat Well Plate,” 396
 EBPG. *see* European Best Practice Guidelines (EBPG)
 EDTNA/ERCA. *see* European Dialysis and Transplant Nurses Association/ European Renal Care Association (EDTNA/ERCA)
- education
 carer involvement in, 74–6
 patient, 74–6, 99
 psychological perspectives on, 93–4
 for PD patients, 270–3
 in predialysis phase of CKD, 140–2, 144
 eGFR. *see* estimated GFR (eGFR)
 electrolyte(s)
 in acetate, 193
 11th Evacuation Hospital, Korea-8, 7
 embolism
 air
 during HD, 222–3, 223–4
 emotional support
 in living relation donation, 310
 in preoperative management of renal transplant recipients, 314
 encapsulating peritoneal sclerosis (EPS), 261
 Encourage Autonomous Self-Enrichment (EASE) patient education programme, 82
 end of life
 symptoms toward, 342–5
 assessment of, 343
 described, 342–3
 management of, 343–5
 end-of-life care. *see also* palliative care
 spirituality in, 346
 End-of-Life Care Strategy, 338
 endothelium
 capillary, 237, 237
 end-stage kidney disease (ESKD), 127
 investigations and procedures in, 148
 PD for, 235
 renal transplantation for, 277
 as cost-effective care, 278
 energy
 lack of
 end-of-life care related to, 344
 energy requirements
 degree of renal function *vs.*, 369, 369
 in dialysis patients, 382–3, 383
 nutrition-related, 379–80
 Engelberg, J., 6
 Engin, E., 90
 environment(s)
 hyperosmotic
 renal processes in creation of, 32–3
 local *see* local environment
 eosinophil(s)
 in WBC count, 158
 EPS. *see* encapsulating peritoneal sclerosis (EPS)
Equity and Excellence: Liberating the NHS, 59, 413
 ERD. *see* established renal disease (ERD)
 ERF. *see* established renal failure (ERF)
 erythropoietic stimulating agents (ESAs), 147
 in anaemia control in stage 4 CKD, 137–8
 poor response to, 162
 erythropoietin
 kidney production of
 renal processes in, 41–2
 ESAs. *see* erythropoietic stimulating agents (ESAs)
 ESKD. *see* end-stage kidney disease (ESKD)
 ESPEN. *see* European Society for Clinical Nutrition and Metabolism (ESPEN)
 established renal disease (ERD)
 in children, 351, 351
 established renal failure (ERF)
 AKI and, 106
 vitamins for patients with, 386, 386
 estimated GFR (eGFR), 29
 in kidney function assessment, 128–9, 166–7

- ethical issues
 - living relation donation-related, 302
- European APD Outcome Study (EAPOS), 260
- European Best Practice Guidelines (EBPG), 419–20
- European Council Directive 2010/32/EU, 148
- European Dialysis and Transplant Nurses Association/ European Renal Care Association (EDTNA/ERCA), 368–9, 418
- European Society for Clinical Nutrition and Metabolism (ESPEN), 389
- European Society of Cardiology, 45
- European Standards for Nephrology Nursing Practice, 418
- EU Tissue and Cells Directive, 304
- everolimus
 - in maintenance immunosuppression, 321
- exit-site infection
 - PD and, 269–70
- extracorporeal circuit
 - in HD, 181–2, 183
 - clotting management-related, 205–6
- Facebook
 - RPSG on, 71–3
- faecal occult blood test (FOBT)
 - in renal profile, 161
- family communication
 - in palliative care, 339
- fatigue
 - end-of-life care related to, 344
- FDA. *see* Food and Drug Administration (FDA)
- fear(s)
 - pre-renal transplant-related, 283–4
- Felton, A., 75
- Fenton, S., 11–12
- ferritin
 - in renal profile, 160
- FFP. *see* fresh frozen plasma (FFP)
- FHN. *see* Frequent Hemodialysis Network (FHN)
- FHN Trial, 190
- fibrin formation
 - in PD, 264
- Fielding, C.A., 220, 221, 225–6
- Figueiredo, A., 271
- Finkelstein, F.O., 270
- Finne, P., 49
- Fischer, M.J., 84
- fistula(s)
 - arteriovenous *see* arteriovenous fistula (AVF)
- “Five Year *Forward View*”, 413
- FK506
 - in maintenance immunosuppression, 319
- flow problems
 - prevention of
 - in TCVCs care, 219
- fluid(s)
 - dialysate, 181, 182
 - in dialysis patients, 383–4
 - in management of CKD and AKI in children, 353
 - normal inputs and outputs of, 25, 26
 - in PD
 - management of, 262
- fluid and electrolyte balance
 - in LRD, 309–10
 - in postoperative care of renal transplant recipients, 324–5
- fluid balance
 - in children, 350
- fluid loss
 - management of
 - in HD prescription, 200–3, 201, 202
- fluid removal
 - in HD prescription, 198–200, 199
- FOBT. *see* faecal occult blood test (FOBT)
- focal segmental glomerulosclerosis, 50, 52
- folate
 - red-cell
 - in renal profile, 160
- Food and Drug Administration (FDA)
 - on CAPD, 12
- Food Standards Agency (FSA)
 - guidelines, 371
- Foote, C., 340
- Fouque, D., 368
- Fournier, C., 303
- Frame, S., 100
- Frequent Hemodialysis Network (FHN), 190, 191
- fresh frozen plasma (FFP)
 - in AKI, 122, 123
- FSA. *see* Food Standards Agency (FSA)
- full blood count
 - in renal profile, 157
- fungal infections
 - after renal transplantation, 327
- fungal peritonitis
 - PD and, 269
- Galen, 9
- gamma glutamyl-transpeptidase (GGT), 155–6
- Ganter, G., 9–10
- gastrointestinal disorders
 - in stage 4 CKD
 - control of, 138
- General Medical Council (GMC), 293
- General Medical Services (GMS)
 - contract
 - in CKD detection and prevention, 131
- genetics
 - of PKD, 54
- GFR. *see* glomerular filtration rate (GFR)
- GGT. *see* gamma glutamyl-transpeptidase (GGT)
- Ginn, H., 368
- Giovanetti diet, 368
- glomerular disease
 - syndromes of, 51
- glomerular filtrate
 - amount and composition of, 29
- glomerular filtration, 27–9, 28, 27
- glomerular filtration rate (GFR), 29
 - estimated, 29
 - kidney function and, 128–9
- glomerulonephritis
 - CKD due to, 49–53, 51
 - clinical manifestations of, 51
 - crenescentic, 50, 52–3
 - described, 49–50, 51
 - histopathology of, 50, 51
 - incidence of, 50
 - membrane-proliferative, 50, 53
 - membranous, 50, 52
 - mesangiocapillary, 50, 53
 - minimal-change, 50
 - post-infection, 50, 53
 - subtypes of, 50–3, 51
 - treatment of, 50
- glomerulosclerosis
 - diffuse intercapillary
 - diabetes mellitus and, 49
 - focal segmental, 50, 52
 - nodular
 - diabetes mellitus and, 49
- glomerulus
 - formation of filtrate in, 28, 28
 - structure of, 27, 27
- glucose
 - in acetate, 193
 - measuring of
 - in renal profile, 154
 - in urine, 163
- glucose-based solutions
 - in PD, 255
- glucose control
 - diabetic nephropathy and, 49
- glycosylated haemoglobin
 - in renal profile, 154–5
- GMC. *see* General Medical Council (GMC)
- GMS. *see* General Medical Services (GMS)

- Goovaerts, T., 85, 142
 Gorer, P., 288
 Gotch, F.A., 258
 Gotloib, L., 239
 graft(s)
 arteriovenous *see* arteriovenous graft (AVG)
 Graham, T., 2
 Greer, R.C., 131
 growth
 factors influencing, 350
 Guarino, J., 6
 Gutch, C.F., 11
 Guthrie, 14
 Guy's Hospital, 288
- Haas, G., 2
 HADS. *see* Hospital Anxiety and Depression Scale (HADS)
 haematinics
 in renal profile, 159–60
 haematocrit (HCT)
 in renal profile, 157, 157
 haematological tests
 full blood count, 157
 Hb, 157, 157
 HCT, 157, 157
 RCC, 157–8
 in renal profile, 156–8, 157
 haematuria
 clinical manifestations of, 51
 PKD and, 55
 haemodiafiltration (HDF)
 continuous
 in AKI, 119, 120
 in HD prescription, 189–90
 intermittent
 in AKI, 118–19
 on-line, 189
 haemodialysis (HD), 179–233
 anticoagulation in, 204–7, 207
 see also anticoagulation, in HD
 assessment and monitoring during, 220–1
 AVF for, 208, 208, 209
 AVG for, 208, 209–10, 209
 challenges related to, 189
 in children, 359–61, 360
 described, 359–60
 home HD, 361
 prescribing dialysis and
 adequacy in, 360–1, 360
 vascular access in, 360
 complications during, 220–6, 222–3
 air embolism, 222–3, 223–4
 DDS, 222, 223
 diabetes mellitus, 224–6
 haemolysis, 222, 223
 monitoring for, 224
 VND, 223, 224
 components for, 180–2, 181, 182
 continuous
 in AKI, 119, 121
 convection in, 185, 186, 187
 CVCs for, 208, 210
 defined, 179
 described, 179
 diabetes and
 management of, 224–6
 dialysate use in, 192–4, 193, 192
 dialysers in, 180, 181, 182, 194–5
 diffusion in, 184–5, 185, 187
 extracorporeal circuit in,
 181–2, 183
 fluid removal during
 dry weight assessment in,
 199–200, 199
 functions of, 180
 history of, 1–9, 5, 7
 the beginning, 1–9, 5, 7
 dialyser development, 5–6
 home HD, 6–8, 7
 later developments, 8–9
 1920s, 2–3
 1930s, 3
 1940s and 1950s, 3–5, 5
 pre-1920s, 2
 vascular access for, 7–8
 home *see* home haemodialysis (HD)
 hospital *vs.* home
 NICE on, 7
 hyperkalaemia and, 384–5
 in-centre
 CAPD with, 86
 intermittent, 118
 machine in, 182–3, 183
 malnutrition related to, 386–9
 see also malnutrition
 molecule size in, 185–6, 187
 more frequent and longer
 in HD prescription, 190–1
 mortality related to, 188
 nocturnal
 in HD prescription, 191
 patient choice for
 psychological perspectives on,
 87–8
 patient's perspective on, 226–7
 prescription for, 188–204 *see also*
 haemodialysis (HD)
 prescription
 principles of, 184–6, 185–7, 187
 refilling during, 200–3, 201, 202
 safety measures for, 180
 types of, 87
 UF in, 186, 187, 187
 vascular access for, 183–4, 207–20
 achieving definitive access
 provision in, 210–11, 212
 AVF in, 208, 208, 209
 AVG in, 208, 209–10, 209
 cannulation techniques, 213–18,
 214–16 *see also*
 cannulation techniques, in
 AVF and AVG function
 preservation
 care of AVF and AVG in, 213
 CVCs in, 208, 210
 history of, 7–8
 TCVCs care in, 218–19
 types of, 208, 208–10, 210, 209
 haemodialysis (HD) clearance,
 195–8, 196
 in HD prescription
 Kt/V, 195–6
 URR, 195–6, 196
 improving, 196–8
 haemodialysis (HD) machine,
 182–3, 183
 haemodialysis (HD) prescription,
 188–204
 blood volume monitoring in, 204
 for children, 360–1, 360
 dialysate in, 192–4, 193, 192
 temperature of, 203–4
 dialysers in, 194–5
 dialysis modality, 188–92, 189
 HDF, 189–90
 home HD, 191–2
 more frequent and longer HD,
 190–1
 nocturnal dialysis, 191
 fluid loss management in, 200–3,
 201, 202
 fluid removal in, 198–200, 199
 challenges related to, 198–9
 dry weight assessment in,
 199–200, 199
 HD clearance in, 195–8, 196 *see*
 also haemodialysis (HD)
 clearance, in HD
 prescription
 IDWG management in, 202–3
 nurse's role in maintaining
 optimal, 198
 peak and trough effect of,
 189, 189
 UFR management in, 202–3
 haemofiltration (HF)
 continuous
 in AKI, 119, 120
 haemoglobin (Hb)
 in renal profile, 157, 157
 haemolysis
 during HD, 222, 223
 haemolytic uraemic syndrome (HUS)
 atypical
 in children, 363
 in children, 363
 haptoglobins
 in renal profile, 161
 Harden, P., 317
 Harvard Medical School
 on brainstem death criteria, 292
 Harwood, L.E., 87, 217, 218

- Havas, K., 82
 Hb. *see* haemoglobin (Hb)
 HbA1c
 in renal profile, 154–5
 hCG. *see* human chorionic gonadotrophin (hCG)
 HCT. *see* haematocrit (HCT)
 HD. *see* haemodialysis (HD)
 HDF. *see* haemodiafiltration (HDF)
 Health and Safety Executive (Sharps Instruments in Healthcare) Regulations
 on effective safety management of sharps, 148
 Health and Social Care Act, 417
 Healthcare Quality Improvement Partnership (HQIP), 421
 Health Foundation–funded programme, 95
 health-related quality of life (HRQoL)
 CKD impacts on, 82
 health research
 PPI in, 76
 Heart of England Foundation NHS Trust, 132
 Henderson, L.W., 190
 Henoch–Schönlein purpura, 52
 heparin
 in anticoagulation, 204–7, 207
 unfractionated *vs.* LMWH
 in clotting management in HD, 206, 207
 heparin-induced thrombocytopenia (HIT)
 heparin use in HD and, 206–7
 hepatitis
 as contraindication to renal transplantation, 280
 hepatitis B
 as contraindication to renal transplantation, 280
 hepatitis C
 as contraindication to renal transplantation, 280
 herpes simplex virus (HSV)
 after renal transplantation, 328
 Hess, C.L.V., 2
 HF. *see* haemofiltration (HF)
 H4RT trial, 190
 high-fibre foods
 in hyperkalaemia
 management, 377
 histocompatibility antigens, 288
 HIT. *see* heparin-induced thrombocytopenia (HIT)
 HIV
 as contraindication to renal transplantation, 280
 HLA. *see* human leukocyte antigen (HLA)
 HLAI. *see* human leukocyte antigen incompatibility (HLAI)
 Holley, J.L., 90
 home haemodialysis (HD), 86
 in children, 361
 in HD prescription, 191–2
 history of, 6–8, 7
 hospital *vs.*, 7
 Hope, J., 81–2
 Hospital Anxiety and Depression Scale (HADS), 98
 HQIP. *see* Healthcare Quality Improvement Partnership (HQIP)
 HRQoL. *see* health-related quality of life (HRQoL)
 HSV. *see* herpes simplex virus (HSV)
 HTA. *see* Human Tissue Authority (HTA)
 Hull Laboratory, 14
 human chorionic gonadotrophin (hCG), 27
 human immunodeficiency virus (HIV). *see* HIV
 human leukocyte antigen (HLA)
 in renal transplantation, 288–9, 289
 human leukocyte antigen incompatibility (HLAI), 288–9
 Human Tissue Act, 293, 304, 305
 Human Tissue Authority (HTA), 293
 human-to-human kidney transplant first, 14
 Hume, 14
 HUS. *see* haemolytic uraemic syndrome (HUS)
 hyaline casts
 in urine, 165
 hygiene
 oral
 as factor in renal transplantation, 282
 hyperacute rejection, 321–2, 322
 hyperamylasaemia, 332
 hypercalcaemia, 153
 hyperkalaemia, 36, 152
 AKI-related
 management of, 114
 dietary management of, 376–7
 HD and, 384–5
 hyperlipidaemia
 dietary interventions for, 372–3
 in NS, 47, 381
 hypernatraemia, 152
 hyperosmotic environment
 renal processes in creation of, 32–3
 hyperphosphataemia, 154
 hypertension
 dietary management of, 371–2
 PKD and, 55–6
 hypoalbuminaemia
 causes of, 390–1
 hypocalcaemia, 153
 described, 38
 hypokalaemia, 36, 152
 hyponatraemia, 152
 hypophosphataemia, 154
 hypotension
 intra-dialytic *see* intra-dialytic hypotension
 hypotension
 IBW. *see* ideal body weight (IBW)
 icodextrin solution
 in PD, 255
 ideal body weight (IBW)
 calculation of, 405
 IDH. *see* intra-dialytic hypotension (IDH)
 IDMS. *see* isotope dilution mass spectrometry (IDMS)
 IDPN. *see* intradialytic peritoneal nutrition (IDPN)
 IDWG. *see* inter-dialytic weight gain (IDWG)
 IHDF. *see* intermittent haemodiafiltration (IHDF)
 IHI. *see* Institute for Healthcare Improvement (IHI)
 IM. *see* instant messaging (IM)
 immediate preoperative care
 for renal transplant recipients, 314, 315
 immune system
 components of, 286–9, 287, 289
 ABO blood groups, 287–8, 287
 histocompatibility antigens, 288
 HLA system, 288–9, 289
 leukocytes, 286
 lymphocytes, 286–7
 major histocompatibility complex, 288–9, 289
 WBCs, 286
 in donor and recipient matching
 for renal transplantation, 286–9, 287, 289
 in LRD, 305, 306
 immunisation
 for immunosuppressed children, 358
 immunoglobulin(s)
 in renal profile, 156
 immunosuppression, 317–21
 after renal transplantation in children, 357
 induction, 317–18
 maintenance, 318–21
 antiproliferative agents in, 319–20
 calcineurin inhibitors in, 318–19
 corticosteroids in, 320–1
 FK506 in, 319

- NICE on, 317
 regimes, 317
 in renal transplantation, 317–21
 history of, 14–15
 impairment(s)
 experience of, 99
 IMPARTS referral pathway. *see*
 Integrating Mental and
 Physical Health Care in
 Research, Training, and
 Services (IMPARTS)
 referral pathway
 impotence
 CKD and, 140
 in-centre haemodialysis (HD)
 CAPD with, 86
 induction immunosuppression,
 317–8
 infant(s)
 renal care of, 349–66
 infection(s). *see also specific types*
 after renal transplantation, 327–8
 see also specific types
 AKI-related
 management of, 116
 PD-related, 264–70, 267 *see also*
 peritonitis, PD and
 prevention of, 265
 prevention of
 TCVCs care in, 218–19
 infection control
 in postoperative care of renal
 transplant recipients, 325
 infertility
 CKD effects on, 140
 information and emotional support
 in preoperative management
 of renal transplant
 recipients, 314
 inheritance
 tissue-type, 305, 306
 Inouye, W.Y., 6
 instagram
 RPSG on, 71, 73–4
 instant messaging (IM), 70
 Institute for Healthcare
 Improvement (IHI),
 414, 415
 insulin
 IP
 during PD for diabetes patients,
 253–4
 Integrating Mental and Physical
 Health Care in Research,
 Training, and Services
 (IMPARTS) referral
 pathway, 101
 inter-dialytic weight gain
 (IDWG), 194
 management of
 in HD prescription, 202–3
 intermittent haemodiafiltration
 (IHDF)
 in AKI, 118–19
 intermittent haemodialysis
 acute
 in AKI, 118
 intermittent peritoneal dialysis
 (IPD), 12
 International Society for Peritoneal
 Dialysis (ISPD), 420
 Nursing Liaison Committee
 of, 271
 International Society of Peritoneal
 Dialysis, 246
 International Society of Renal
 Nutrition and Metabolism
 (ISNMRD), 388, 389, 391
 interstitial nephritis
 acute
 AKI related to, 109–10
 intra-abdominal pressure
 raised
 in PD, 263
 intra-dialytic hypotension (IDH),
 198–200
 reducing
 dialysate temperature in, 203–4
 intra-dialytic peritoneal nutrition
 (IDPN), 395
 intraperitoneal amino acid (IPAA)
 solution
 electrolyte formulation of,
 257, 257
 intraperitoneal (IP) insulin
 during PD for diabetes patients,
 253–4
 intravascular clotting
 NS and, 48
 intravenous pyelogram (IVP)
 in renal assessment, 172–3
 INVOLVE, 79
 IP. *see* intraperitoneal (IP)
 IPAA solution. *see* intraperitoneal
 amino acid (IPAA) solution
 IPD. *see* intermittent peritoneal
 dialysis (IPD)
 ischaemia
 cold
 in deceased donation, 300–1
 warm
 in deceased donation, 300
 ISNMRD. *see* International Society
 of Renal Nutrition and
 Metabolism (ISNMRD)
 isotope dilution mass spectrometry
 (IDMS), 166
 ISPD. *see* International Society for
 Peritoneal Dialysis (ISPD)
 Israel Penn International Transplant
 Tumor Registry, 279
 IVP. *see* intravenous pyelogram (IVP)
- Jayanti, A., 83
 JBDS-IP. *see* Joint British Diabetes
 Societies for Inpatient Care
 (JBDS-IP)
 Jefferies, H.J., 190
 Joboshi, H., 82
 Joint British Diabetes Societies
 for Inpatient Care
 (JBDS-IP), 225
 Jones, C., 379
 juxtaglomerular apparatus, 35
 KDIGO. *see* Kidney Disease
 Improving Global
 Outcomes (KDIGO)
 KDOQI. *see* Kidney Disease
 Outcome Quality Initiative
 (KDOQI)
 Keddo, M., 89
 Kee-Low, J., 100
 Kelly, C.J., 49
 Kempf, J.P., 302
 Kerr, M., 105
 Keskin, G., 90
 KHDE. *see* *Kidney Health:
 Delivering Excellence*
 (KHDE)
 kidney(s)
 artificial
 history of, 2
 described, 21–2, 22–3
 Kolff–Brigham, 4
 multisystem diseases affecting,
 56–7
 structure and functions of, 21–7,
 22–5, 25, 26 *see also*
 kidney function; kidney
 function tests; specific
 structures, e.g., nephron
 nephron, 22–3, 24, 25
 urinary concentration,
 25–6, 26
 urinary content, 27
 urinary volume, 24–5, 26
 versatility of urine, 23–4
 kidney biopsy, 168–71
 contraindications to, 169
 patient care following, 170
 patient preparation for, 169
 procedure, 169–70
 risk factors for, 168–9
 in transplant recipients,
 170–1
 Kidney Care, 60, 133, 346
 kidney care
 QI in, 413–22 *see also* quality
 improvement (QI)
 kidney disease(s). *see specific types*
 and renal disease(s)
 end-stage *see* end-stage kidney
 disease (ESKD)

- Kidney Disease Improving Global Outcomes (KDIGO), 371–3, 375, 378, 389, 391, 398–9
 on AKI management, 116
 Clinical Practice Guideline of, 96–101, 100
- Kidney Disease Improving Global Outcomes (KDIGO) staging classification, 113, 113
- Kidney Disease Outcome Quality Initiative (KDOQI)
 best practice guidelines from, 418–19
 of National Kidney Foundation, 43
- Kidney Disease Quality Outcome Initiative (KDOQI)
 classification
 of CKD, 129–31, 130
- kidney donors
 deceased, 291–302, 291, 294, 298, 300 *see also* deceased donation
 living
 psychological perspectives on, 96–101, 100
 living relation, 302–10, 304, 306, 307, 308 *see also* living relation donation (LRD)
 potential
 clinical care of, 297
 organ-specific contraindications for, 292–3, 294
- kidney function
 assessment of
 eGFR in, 128–9
 GFR and, 128–9
- kidney function tests, 165–8
 CKD 5 chromium EDTA GFR, 168
 creatinine clearance, 167–8
 eGFR, 166–7
 protein excretion measurement, 167
- Kidney Health: Delivering Excellence (KHDE)*, 188, 416
- kidney injury
 acute, 105–25 *see also* acute kidney injury (AKI)
- kidney patient associations (KPA), 72
- Kidney Patient Involvement Network (KPIN), 78–9
- Kidney Quality Improvement Partnership (KQIP), 192
 on patient safety, 416–17
- Kidney Research and Education Initiative (KREI)
 at City University London, 75
- Kidney Research User Group (KRUG)
 at London South Bank University, 75
- kidney transplantation. *see* renal transplantation
- kidney tubules
 bicarbonate reabsorption in, 40, 41
- Kiil dialyser, 5, 6, 7
- Kiil, F., 5
- Kjellstrand, C., 13
- Kolff–Brigham dialysis machine, 4, 5
- Kolff–Brigham kidney, 4
- Kolff dialyser, 3–4
- Kolff, W.J., 3, 10
- Kopple, J.D., 380
- Kop, P.S.M., 10
- Korzon, W., 4
- KPAs. *see* kidney patient associations (KPA)
- KPIN. *see* Kidney Patient Involvement Network (KPIN)
- KQIP. *see* Kidney Quality Improvement Partnership (KQIP)
- KREI. *see* Kidney Research and Education Initiative (KREI)
- Kronung, G., 214
- KRUG. *see* Kidney Research User Group (KRUG)
- Kt/V
 in HD clearance, 195–6
 measurement of, 195–6
- Kubara, H., 214
- lack of energy
 end-of-life care related to, 344
- lactate dehydrogenase (LDH)
 in renal profile, 161
- Lambie, S.H., 197
- Landsteiner, 287
- Lasker, 11
- Lasker cyclor machine, 11–12
- LDH. *see* lactate dehydrogenase (LDH)
- Leonards, J., 5
- lethargy
 NS and, 48
- leukocyte(s), 286
- leukocytosis, 158
- LFTs. *see* liver function tests (LFTs)
- lipid(s)
 in PD
 problems related to, 262–3
 in renal profile, 155
- Li, P.K.T., 253
- liver function tests (LFTs)
 albumin, 155
 bilirubin, 156
- complement, 156
 creatine kinase, 156
 immunoglobulins, 156
 plasma total protein, 155–6
 in renal profile, 155–6
 serological tests, 156
 viral serology, 156
- liver injury
 acute
 AKI related to, 110
- Living Donor Kidney Transplant Programme, 305
- living donor transplantation
 for children, 356–7
- living kidney donors
 psychological perspectives on, 96–101, 100
- living relation donation (LRD), 302–10, 304, 306, 307, 308
 altruism, 302–3
 assessment and preparation of donors, 306–8, 307
 benefits for transplant recipients, 303
 buying and selling of organs, 304
 for children, 357
 discharge, 310
 donor and recipient matching, 305
 emotional support, 310
 ethical issues, 302
 future for, 305
 hydration, 309–10
 immunological aspects, 305, 306
 living unrelated donation, 303
 nephrectomy, 308–9
 NLDKSS, 304, 305
 physical wellbeing, 302
 postoperative management, 309
 preoperative care for donor, 308, 308
 psychological issues, 305–6
 psychological wellbeing, 302
 transplant rates, 303, 304
 wound management, 310
- living unrelated donation, 303
- LMWH. *see* low-molecular weight heparin (LMWH)
- local environment
 described, 32
 maintenance of, 33
 renal processes in creation of, 32–3
- Loft, R., 82
- London South Bank University
 KRUG at, 75
- loop of Henle, 22–3, 24
- low-molecular weight heparin (LMWH)
 in anticoagulation, 204–7, 207
 in clotting management in HD *vs.* unfractionated heparin, 206, 207

- LRD. *see* living relation donation (LRD)
- lymphatic draining
during PD, 238
- lymphocyte(s), 286–7
in WBC count, 158
- MacManus, B., 93
- macula densa, 34, 35
- magnesium
renal processes in regulation of, 36–8, 38, 39
- magnetic resonance imaging (MRI)
nuclear
in renal assessment, 173
in renal assessment, 173
- major histocompatibility complex, 288–9, 289
- malignancy
as contraindication to renal transplantation, 279
- Malinow, M.R., 4
- malnutrition
in body composition assessment
treatment of, 392
body composition changes with, 378–9
dietary management of, 378–80
HD- and PD-related, 386–9
causes of, 387–8
detection of, 388
dietary assessment
methods, 389
effects of, 386–7
management of, 388–9
nutritional status assessment in, 388–9
PEW, 388
NS and, 48
nutritional assessment of, 378
nutritional determinants related to, 379–80
PD and, 258
treatment of, 392
- Malnutrition Universal Screening Tool (MUST), 388, 389, 392
- MAMC. *see* mid-arm muscle circumference (MAMC)
- Maxwell, M., 10, 11
- Maxwell technique, 10
- McCarthy, K., 210
- McClure, D.L., 89
- McGuigan, H., 2
- McIntyre, C.W., 196, 200
- MDRD formula. *see* Modification of Diet in Renal Disease (MDRD) formula
- Mead, 420
- Medawar, Sir P., 14–15
- medication(s)
nonconcordance of
risk factors for, 100, 100
in postoperative care of renal transplant recipients, 325–6
- Mediterranean diet, 373
- Meghani, S., 338
- Mehrotra, R., 252
- membrane-proliferative
glomerulonephritis, 50, 53
- membrane resistance, 239
- membranous glomerulonephritis, 50, 52
- Mental Capacity Act
principles underlying, 341, 341
- mental health
PPI in, 76
- Merrill, J.P., 14
- mesangial proliferative nephritis, 50, 52
- mesangiocapillary
glomerulonephritis, 50, 53
- mesothelium, 237, 237
- metabolic acidosis, 42
AKI-related
management of, 115
- Michael Reese Hospital, 4
- microalbuminuria, 164
- micronutrient(s)
nutritional requirements for, 380
- mid-arm muscle circumference (MAMC), 378
in body composition
assessment, 390
- Miller, D.C., 14
- mineral(s)
requirements in dialysis
patients, 386
- mineral and bone disorders
in renal profile
tests for, 151, 153–4
- minimal-change
glomerulonephritis, 50
- Model for Improvement, 420–1, 421
- Modification of Diet in Renal Disease (MDRD)
formula, 166
NSF for Renal Services on, 128, 129
- Modification of Diet in Renal Disease (MDRD)
study, 368
- molecular weight, 239
- molecule(s)
in HD
sizes of, 185–6, 187
- Molnar, 251
- monocyte(s)
in WBC count, 158
- Morton, R.L., 226, 336
- Mouelhi, Y., 94
- Mount Sinai Hospital, 4
- MRI. *see* magnetic resonance imaging (MRI)
- multisystem diseases
renal effects of, 56–7
- muromab-CD3
in immunosuppression
induction, 318
- Murray, J.E., 14
- muscle wasting
NS and, 47
- Muslim Law Council, 294
- MUST. *see* Malnutrition Universal Screening Tool (MUST)
- mycophenolate mofetil
in maintenance
immunosuppression, 320
- myoglobulin
in urine, 165
- myoglobulinuria, 165
- National Academy of Sciences, 15
- National Confidential Enquiry into Patient Outcome and Death (NCEPOD)
on AKI, 105
- National Co-operative Dialysis study, 258
- National Health Service (NHS), 83
on AKI costs, 105
Next Stage Review report of, 413
- National Health Service (NHS)/British Heart Foundation Guidelines, 373
- National Institute for Clinical Excellence
on home *vs.* hospital HD, 7
- National Institute for Health and Care Excellence (NICE)
guidelines, 85, 137, 138, 141, 142, 152, 251, 261, 293, 369, 371–2, 374, 389, 394, 415
on AKI, 105–6, 113
on albumin, 164
clinical audit tools for, 420
on home HD, 191–2
on immunosuppressive therapy for renal transplantation, 317
on patient safety, 417–18, 418, 417
on RRT, 417, 418
- National Institute for Health Research (NIHR), 79
- National Institutes of Health (NIH)
on nutritional health of patient prior to dialysis, 368
- National Kidney Foundation (NKF)
DOQI of, 368
KDOQI of, 43

- National Living Donor Kidney Sharing Scheme (NLDKSS), 304, 305
- National Organ Donor Registry, 313
- National Organ Retrieval Service (NORS), 311
- National Register, 297
- National Renal Data Set, 373
- National Research Council, 15
- National Service Framework (NSF)
for Renal Services, 128
on MDRD formula, 128, 129
on patient safety, 415–16
requirements of, 128
- National Service Framework for Renal Services: Working for Children and Young People*, 416
- nausea and vomiting
end-of-life care related to, 344
- Naval Hospital, San Francisco, 10
- Navaneethan, S.D., 91
- NCEPOD. *see* National Confidential Enquiry into Patient Outcome and Death (NCEPOD)
- Necheles, H., 3
- negative-pressure monitoring
history of, 8
- nephrectomy
bilateral
technique, 299–300, 300
deceased donation
technique, 299–300, 300
living relation donor, 308–9
- nephritis
acute interstitial
AKI related to, 109–10
mesangial proliferative, 50, 52
- nephron, 22–3, 24, 25
- nephropathy
diabetic, 48–9
reflux, 54
- nephrosclerosis
CKD due to, 45
- nephrosis
CKD due to, 45–8, 46, 47
- nephrotic syndrome (NS)
causes of, 46, 46
in children, 48, 355–6
congenital NS, 356
nursing care for, 355–6
CKD due to, 45–8, 46, 47
clinical features of, 46–8, 47
clinical manifestations of, 51
congenital
in children, 356
described, 45, 381
dietary management of, 381, 381
hyperlipidaemia in, 381
management of, 47–8, 381, 381
pathology of, 46, 47
protein reduction in, 381
steroid sensitive, 355
symptoms of, 45
- nephrotoxicity
AKI related to, 111, 111
- neutrophil(s)
in WBC count, 158
- new-onset diabetes after transplantation (NODAT), 397
- Next Stage Review report of NHS, 413
- NHS. *see* National Health Service (NHS)
- NHS England, 349
- NHS Improvement, 414
- NHS Right Care
decision aids for established renal failure and dialysis, 93
- NICE guidelines. *see* National Institute for Health and Care Excellence (NICE) guidelines
- NIH. *see* National Institutes of Health (NIH)
- NIHR. *see* National Institute for Health Research (NIHR)
- NIS Organ Donor register, 312
- Nistor, I., 190
- NKF. *see* National Kidney Foundation (NKF)
- NLDKSS. *see* National Living Donor Kidney Sharing Scheme (NLDKSS)
- nocturnal dialysis
in HD prescription, 191
- nocturnal haemodialysis (HD)
in haemodialysis prescription, 191
- NODAT. *see* new-onset diabetes after transplantation (NODAT)
- nodular glomerulosclerosis
diabetes mellitus and, 49
- nonconcordance of medication
risk factors for, 100, 100
- nondialytic (conservative) care, 335–48
described, 341–2, 342
importance of, 336
introduction, 335
number of patients requiring, 336
- normal blood sample
analysis of, 150–1, 151
- NORS. *see* National Organ Retrieval Service (NORS)
- North Bristol NHS Trust, 72
- NS. *see* nephrotic syndrome (NS)
- NSF. *see* National Service Framework (NSF)
- NSF for Children, Young People, and Maternity Services, 416
- nuclear magnetic resonance imaging (MRI)
in renal assessment, 173
- nurse(s)
experienced and well-trained
with cannulation techniques in AVF and AVG function preservation, 218
in HD prescription, 198
- nursing admission procedure
in preoperative management of renal transplant recipients, 313, 313
- nursing care
for NS in children, 355–6
- Nursing Liaison Committee of ISPD, 271
- nutrition
in AKD management, 367–411
see also dietary interventions
in AKI management, 115–16
intradialytic peritoneal, 395
introduction, 367
malnutrition-related requirements for, 379–80
in stage 4 CKD, 136
- nutritional peritoneal dialysis (PD), 395
- “Nutrition in CKD,” 378, 379
- obesity
as factor in renal transplantation, 282
- occult blood
in renal profile, 161
- occupational exposures
to BBV, 148
- OCPD. *see* optimised cycling peritoneal dialysis (OCPD)
- oedema
NS and, 46–7, 47
- O’Hare, A.M., 339
- Ohtake, Y., 84
- Oka, M., 82
- Oliver, S.W., 211
- ongoing care
for renal transplant recipients, 330
- on-line haemodiafiltration (HDF), 189
- ONS. *see* Oral Nutritional Support (ONS)
- Opelz, G., 16
- optimised cycling peritoneal dialysis (OCPD), 250–1, 251
- oral hygiene
as factor in renal transplantation, 282

- Oral Nutritional Support (ONS)
in body composition assessment, 392–4
- Orem's Theory of Self-Care Deficit, 90
- Oreopoulos, D., 11, 12
- organ(s)
buying and selling of, 304
dealing with, 99
donor *see* donor organs
- Organ Donation Taskforce, 311
- organ preservation
in deceased donation, 300
- osmolality
body, 26, 26
renal processes in regulation of, 33–4, 34
of urine, 163
- osmosis
concepts of, 26
during PD, 238, 238
- osmotic ultrafiltration (UF)
during PD, 239–40
- Ossareh, S., 89, 90
- “Package of Innovation (POI)
for Managing Kidney Disease in Primary Care,” 134
- pain
end-of-life care related to, 344
PKD and, 54
shoulder
PD and, 264
- palliative care, 335–48
advance planning in, 340–1, 341
communication within team
in, 340
defined, 336–7, 337
described, 336–7, 337
dialysis decision-making in, 340
family communication in, 339
introduction, 335
patient communication in, 338–9, 339
psychological issues in, 345–6
recent government and other initiatives on, 337–8
social issues in, 345–6
spiritual care, 346
- Palmer, R.A., 4, 11
- Palmer, S.C., 373
- pancreas-kidney transplantation, 330–2, 331
- pancreatic transplantation, 330–2, 331
- Panel Reactive Antibody (PRA), 290
- papillary necrosis
diabetes mellitus and, 49
- parallel dialyser, 6
- parathyroid hormone (PTH)
in phosphate and calcium control, 31, 37–8, 38, 39
in renal profile, 154
- Parker, D., 94
- Patient Activation Measure, 226
- patient and public involvement. *see* public and patient involvement (PPI)
- patient communication
in palliative care, 338–9, 339
- patient decision aids (PDAs), 141
- patient education, 99
psychological perspectives on, 93–4
- patient experience survey, 60–70
- patient involvement
described, 60
in renal nursing care, 59–74
case studies, 61–5, 69–70
PREMs, 60–70, 226
reflection on, 70
social media in, 70–4
in renal nursing education, 74–6
in renal research, 77–8, 77
- Patient Outcome Scale, 343
- Patient Reported Experience Measures (PREMs), 60–70, 226
- Patient Reported Outcome Measure (PROM), 226
- patient safety, 414–18, 415, 417, 418
clinical practice guidelines, 415
conversation about, 414, 415
defined, 414
IHI on, 414, 415
KQuIP on, 416–17
NICE on, 417–18, 418, 417
NSF on, 415–16
- PCR. *see* protein catabolic rate (PCR)
- PCT. *see* proximal convoluted tubule (PCT)
- PD. *see* peritoneal dialysis (PD)
- PDAs. *see* patient decision aids (PDAs)
- PDC test. *see* Personal Dialysis Capacity (PDC) test
- PDEPs. *see* predialysis education programmes (PDEPs)
- PDSA cycles. *see* Plan-Do-Study-Act (PDSA) cycles
- Pedrin, M.T., 368
- peptic ulceration
in evaluation for renal transplantation, 281–2
- peritoneal cavity, 236, 236
- peritoneal dialysis (PD), 235–76. *see also specific types, e.g., continuous ambulatory peritoneal dialysis (CAPD)*
- access and exit site care, 242–8, 243, 242, 245
- acute
in AKI, 121
- adequacy of
assessment of, 257–60, 259
creatinine as measure of, 258
protein nutrition in, 258
urea as measure of, 258, 259
wellbeing in, 258, 260
- assisted, 86
- automated *see* automated peritoneal dialysis (APD)
- blood-stained effluent in, 264
- cardiovascular problems in, 262–3
- catheters in, 242–6, 243, 242, 245
see also peritoneal dialysis (PD) catheters
- in children, 358, 359
- complications of
infectious, 264–70, 267 *see also* peritonitis, PD and
- constipation in, 263–4
- continuous ambulatory *see* continuous ambulatory peritoneal dialysis (CAPD)
- continuous cycling, 13, 249–50, 250
- for diabetes patients, 252–4
blood glucose control in, 252–3
IP insulin in, 253–4
- drainage problems in, 263
- education and training for patients, 270–3
barriers to learning, 270–1
learning environment, 271
recommendations for training within renal units, 271–2
what to teach, 272–3
- for ESKD, 235
- fibrin formation in, 264
- fluid management in, 262
- goals of, 257–8
- history of, 9–13
APD, 1
CAPD, 12
catheter, 10–11
current, 13
home, 11–12
- home
history of, 11–12
- infectious complications of, 264–70, 267 *see also* peritonitis, PD and
- intermittent, 12
- introduction, 235–6
- lipid problems in, 262–3
- malnutrition related to, 258, 386–9 *see also* malnutrition
- malpositioned catheter in, 264
- nutritional, 395

- peritoneal dialysis (PD) (*cont'd*)
 optimised cycling, 250–1, 251
 patient selection for, 251–2, 252
 psychological perspectives
 on, 89
 perioperative care of patient, 246
 PET in, 240–2, 241
 physiology of, 236–42, 236–9,
 241
 blood supply, 238
 components in, 236–42, 236–9,
 241 *see also* peritoneum;
 specific components, e.g.,
 peritoneal cavity
 convection, 239–40
 diffusion, 239, 239
 lymphatic draining, 238
 osmosis, 238, 238
 osmotic UF, 239–40
 peritoneal membrane transport
 characteristics, 238–40,
 239, 238
 peritoneal permeability
 measurement, 240
 postoperative care of patient,
 246–7
 preoperative care of patient,
 244–6, 245
 problem solving in, 262–4
 protein loss in, 262
 psychological preparation of
 patient, 244
 raised intra-abdominal pressure
 problems in, 263
 shoulder pain during, 264
 sodium sieving in, 262
 solution formulation, 254–7,
 254, 257
 bicarbonate/lactate-based
 solutions, 255–7
 glucose-based solutions, 255
 icodextrin solution, 255
 introduction, 254, 254
 IPAA solution, 257, 257
 for special needs
 advances in, 13
 tidal, 250, 250
 tubing kinks in, 263
 types of, 248–51, 248, 250, 251,
 252 *see also specific types,*
 e.g., continuous
 ambulatory peritoneal
 dialysis (CAPD)
- peritoneal dialysis (PD) catheters,
 242–6, 243, 242, 245
 access and exit site care, 242–8,
 243, 242, 245
 immobilisation of, 247
 insertion techniques, 245–6, 245
 long-term care of exit site, 247–8
- parts of, 242, 242
 perioperative care of patient, 246
 postoperative care of patient,
 246–7
 preinsertion preparation of
 patient, 244
 preoperative care of patient,
 244–6, 245
 removal of
 indications for, 247–8
 swimming and bathing with, 247
 types of, 243–4, 243
Peritoneal Dialysis International,
 268
 Peritoneal Equilibrium Test (PET),
 240–2, 241
 peritoneal interstitium, 237, 237
 peritoneal membrane
 layers of, 236–7, 237
 long-term changes to, 261
 transport characteristics
 during PD, 238–40, 239, 238
 peritoneal nutrition
 intra-dialytic, 395
 peritoneal permeability
 measurement of, 240
 peritoneum
 anatomy and physiology of,
 236–42, 236–9, 241
 blood supply to, 238
 peritonitis
 culture-negative
 PD and, 269
 PD and, 264–70, 267
 causes of, 265–6
 culture-negative peritonitis, 269
 diagnosis of, 266, 267
 exit-site and tunnel infection,
 269–70
 fungal peritonitis, 269
 obtaining effluent specimen,
 267–8
 permeability changes during,
 268–9
 prevention of, 265
 relapsing peritonitis, 269
 sites of, 266
 Personal Dialysis Capacity (PDC)
 test, 240
 PET. *see* Peritoneal Equilibrium Test
 (PET)
 Peter Brent Brigham Hospital, 4, 14
 PEW. *see* protein energy wasting
 (PEW)
- pH
 fall in
 renal processes in correcting,
 40–1, 42
 plasma
 rise in, 41, 42
- phlebotomy, 148–50, 149
 choice of vein in CKD patients,
 149, 150, 149
 correct collection procedure, 149
 safety of healthcare personnel,
 148–50, 149
 WHO on, 148
- phosphate
 metabolism of
 dietary management of, 374
 PTH in control of, 31
 renal processes in regulation of,
 36–8, 38, 39
 in renal profile, 151, 153–4
 phosphate binders, 375–6
 phosphate reduction
 dietary, 375
 phosphorus
 in diet, 153
 foods with high and low content
 of, 408–9
 requirements in dialysis patients,
 383, 385
- physical wellbeing
 in living relation donation, 302
 Piccoli, G.B., 140
 PKD. *see* polycystic kidney disease
 (PKD)
- plain abdominal x-ray
 in renal assessment, 171
 Plan-Do-Study-Act (PDSA)
 cycles, 420
- plasma
 fresh frozen *see* fresh frozen
 plasma (FFP)
 plasma exchange
 therapeutic
 in AKI, 122
 plasma pH
 fall in
 renal processes in correcting,
 40–1, 42
 rise in, 41, 42
 plasma total protein
 in renal profile, 155–6
 podocyte(s), 27
 POI. *see* “Package of Innovation
 (POI) for Managing Kidney
 Disease in Primary Care”
- polyarteritis nodosa
 renal effects of, 57
 polyclonal antibodies
 ALG, ATG
 in immunosuppression
 induction, 318
 polycystic kidney disease (PKD)
 autosomal dominant, 54
 autosomal recessive, 54
 CKD due to, 54–6, 55, 56
 clinical features of, 54–6

- in evaluation for renal transplantation, 281
- genetics of, 54
- management of, 54–6
- pathology of, 54, 55, 56
- polyoma virus
 - after renal transplantation, 328
- Popovich, R., 12
- portable/wearable equilibrium dialysis technique, 12
- positive changes
 - experiences of, 99
- post-infection glomerulonephritis, 50, 53
- postrenal failure
 - AKI related to, 112
- potassium
 - in acetate, 193
 - aldosterone in controlling, 36
 - in dialysis patients, 383, 384–5
 - foods with high, medium, and lower content of, 409–10
 - in hyperkalaemia management, 377
 - in renal profile, 151, 152–3
- potassium disorders
 - in stage 4 CKD
 - control of, 139
- potassium exchange resins, 377
- potassium portions (exchanges), 410–11
- potential kidney donors
 - clinical care of, 297
 - organ-specific contraindications for, 292–3, 294
- Power, A., 94
- PPI. *see* public and patient involvement (PPI)
- PRA. *see* Panel Reactive Antibody (PRA)
- Prabhakar, S.R.G., 221
- predialysis dietary interventions
 - current concepts on, 369–71, 370
- predialysis education programmes (PDEPs), 141–2, 143–4
- predialysis phase
 - of CKD
 - education in, 140–2, 144
- prednisolone
 - in maintenance
 - immunosuppression, 320
- pre-emptive transplantation
 - for children, 357
- Preferred Place of Care
 - document, 341
- PREMs. *see* Patient-Reported Experience Measures (PREMs)
- pre-registration teaching
 - patient and carer involvement in, 75–6
- prerenal renal failure
 - AKI related to, 107–8, 109
- pretransplant cross-match
 - in donor and recipient matching for renal transplantation, 289–90
- primary care
 - CKD management in
 - clinical guidelines for, 131
- PROM. *see* Patient Reported Outcome Measure (PROM)
- prophylactic antibiotics
 - prior to PD, 244
- protein(s)
 - Bence Jones
 - in urine, 164
 - plasma total
 - in renal profile, 155–6
 - reduction of
 - in NS management, 381
 - requirements for
 - degree of renal function *vs.*, 369, 369
 - in dialysis patients, 382, 383
 - nutritional, 379
 - Tamm–Horsfall, 165
 - in urine, 163–4
- protein catabolic rate (PCR), 389
- protein energy wasting (PEW), 388
 - in body composition
 - assessment, 391
- protein excretion
 - in kidney function
 - assessment, 167
- protein loss
 - in PD, 262
- protein nutrition
 - in PD adequacy assessment, 258
- proteinuria
 - causes of, 164
 - clinical manifestations of, 51
 - NS and, 47
 - PKD and, 55
- proximal convoluted tubule (PCT)
 - reabsorption in, 30, 31
- pruritus
 - end-of-life care related to, 345
- psychological issues
 - in LRD, 305–6
 - in palliative care, 345–6
- psychological perspectives, 81–104
 - CKD-related, 81–104, 84–6
 - depression-related, 89–90
 - HD-related, 87–8
 - HRQoL in, 82
 - introduction, 81–4
 - on kidney transplantation, 96–101, 100
 - on nondialytic conservative kidney management, 96
 - on patient choice for dialysis, 86–9
 - patient education-related, 93–4
 - PD-related, 89
 - on psychonephrology, 84
 - RRT-related, 81
 - self-care-related, 94–5, 95
 - sexuality-related, 91–3, 91
- psychological wellbeing
 - in living relation donation, 302
- psychonephrology
 - psychological perspectives on, 84
- PTH. *see* parathyroid hormone (PTH)
- public and patient involvement (PPI)
 - in health research, 76
 - measuring impact of, 79
 - in mental health, 76
- Public Health England, 148
- Public Health Service Hospital, 14
- Putnam, T., 9
- pyelogram(s)
 - in renal assessment
 - IVP, 172–3
 - retrograde pyelogram, 173
- pyelonephritis
 - CKD due to, 53–4
 - clinical features of, 53
 - diabetes mellitus and, 49
 - disease progression and prognosis, 53–4
 - treatment of, 53
- QI. *see* quality improvement (QI)
- QOF initiative. *see* Quality and Outcomes Framework (QOF) initiative
- Quality and Outcomes Framework (QOF) initiative, 85, 131
- quality healthcare
 - components of, 414
- quality improvement (QI)
 - defined, 414
 - introduction, 413
 - in kidney care, 413–22 *see also* patient safety
 - best practice guidelines for, 418–19, 419
 - introduction, 413
 - methods, 420–2
 - patient safety, 414–18, 415, 417, 418
- Quinton, G., 8
- radiographic investigations, 171–6
 - bone density scan, 171
 - CAT, 173
 - CT, 173
 - DEXA scan, 171, 390
 - Doppler studies, 174

- radiographic investigations (*cont'd*)
 IVP, 172–3
 MRI, 173
 nuclear MRI, 173
 plain abdominal x-ray, 171
 renal angiogram, 175–6
 renal scans, 175
 renograms, 174–5
 retrograde pyelogram, 173
 skeletal x-rays, 171–2
 US, 173–4
 rapamycin
 in maintenance
 immunosuppression, 320–1
 Ravani, P., 218
 RCC. *see* red cell count (RCC)
 reabsorption, 29–31, 31
 in DCT, 30–1, 31
 mechanisms of, 29–30, 31
 in PCT, 30, 31
 selective, 29–31, 31
 Rebollo Rubio, A., 86
 recurrent disease
 as contraindication to renal
 transplantation, 279–80
 red cell count (RCC)
 in renal profile, 157–8
 red-cell folate
 in renal profile, 160
 reflux nephropathy, 54
 relapsing peritonitis
 PD and, 269
 religious beliefs
 deceased donation and, 293–5
 renal amyloidosis, 56–7
 renal angiogram, 175–6
 renal artery stenosis
 CKD due to, 43–5, 44, 45
 Renal Association, 192, 195, 205–6,
 208, 225, 242, 255, 257,
 260, 306, 371, 375,
 378, 379
 best practice guidelines from,
 419, 419
 Clinical Practice Guideline of,
 89, 195
 e-guide for CKD, 132
 on HD prescription, 188
 on interpreting eGFR results,
 128–9
 renal care
 of infants, children, and young
 adults, 349–66 *see also*
 specific types and children
 physiology in childhood impact
 on, 350–1, 351
 renal disease(s). *see also specific*
 types and chronic kidney
 disease (CKD)
 in adolescents
 transition to adult services, 363–4
 advanced *see* advanced kidney
 disease (AKD)
 in childhood, 350
 diabetic
 CKD due to, 48–9
 established
 in children, 351, 351
 investigations and procedures in,
 147–77
 biochemical blood tests, 150–65
 see also specific types and
 biochemical blood tests
 introduction, 147–8
 kidney biopsy, 168–71
 kidney function tests, 165–8
 see also kidney function
 tests
 for mineral and bone disorders,
 151, 153–4
 phlebotomy, 148–50, 149
 radiographic investigations,
 171–6 *see also*
 radiographic investigations
 urine-related, 162–5, 162
 PKD *see* polycystic kidney disease
 (PKD)
 process of
 anatomy and physiology related
 to, 21–58
 renal failure
 AKI related to, 108, 109, 110
 established
 AKI and, 106
 prerenal
 AKI related to, 107–8, 109
 renal function
 degree of
 vs. protein and energy
 requirements, 369, 369
 renal nursing care
 patient and carer involvement in,
 59–74 *see also carer*
 involvement; patient
 involvement
 renal nursing education. *see also*
 education
 patient and carer involvement in,
 74–6
 renal nutrition, 367–411. *see also*
 dietary interventions
 Renal Nutrition Group
 of BDA, 369
 Renal Patient Support Group
 (RPSG)
 on blogspot, 71, 73
 components of, 73
 on Facebook, 71–3
 on instagram, 71, 73–4
 on ResearchGate, 73
 statistics of, 72, 72
 on Twitter, 71
 renal process(es), 27–43. *see also*
 specific types
 acid–base control, 39
 aldosterone and control of body
 potassium content, 36
 basic, 27–43 *see also specific*
 types, e.g., secretion
 bicarbonate buffering system,
 39–40
 bicarbonate ion concentration
 control, 40, 41
 blood pressure–renal function
 relationship, 42–3
 in calcium, phosphate, and
 magnesium regulation,
 36–8, 38, 39
 concentration and dilution of
 urine, 32
 correcting acid–base fluctuations
 in healthy persons,
 40–1, 42
 creation of local environment, 32–3
 erythropoietin production, 41–2
 excretion of drugs and drug
 metabolites, 32
 glomerular filtration, 27–9, 28, 27
 hyperkalaemia, 36
 hypokalaemia, 36
 in phosphate and calcium control,
 37–8, 38, 39
 regulation of body fluid volume
 and osmolality, 33–4, 34
 renin–angiotensin–aldosterone
 pathway, 34–5, 35
 secretion, 31
 selective reabsorption, 29–31, 31
 renal profile
 biochemical blood tests in,
 151–4, 151
 Renal Registry, 60, 83, 84, 132, 188,
 195, 336, 354
 renal replacement therapy (RRT)
 for AKI, 106, 118–23, 120–2
 in children, 362–3
 in children, 356–8, 358
 continuous *see* continuous renal
 replacement therapy
 (CRRT)
 dietary management during,
 367–411 *see also dietary*
 interventions
 history of, 8–9
 increase in use of, 336
 investigations required prior to,
 358, 358
 median age of patients
 starting, 336
 NICE quality statements for,
 417, 418
 patients requiring
 prevalence of, 336

- prevalence of, 16, 17
- psychological perspectives related to, 81 *see also* psychological perspectives
- renal replacement therapy option education (RRTOE), 85
- renal research
 - patient and carer involvement in, 76–8, 77
- renal scans
 - in renal assessment, 175
- renal transplantation, 277–334
 - age as factor in, 280, 281
 - for AKD, 395–7
 - bone disease after, 397
 - for children, 356–8, 358 *see also* children, renal transplantation for
 - complications of, 326–8
 - acute rejection, 326
 - ATN, 326
 - infections, 327–8
 - renal dysfunction, 326
 - urological, 327
 - vascular, 326–7
 - contraindications to, 279–80
 - as cost-effective care, 278
 - CVD following, 396–7
 - deceased donation, 291–302, 291, 294, 298, 300 *see also* deceased donation
 - diabetes mellitus after, 397
 - donor and recipient matching, 286–90, 287, 289
 - immune system in, 286–9, 287, 289
 - in LRD, 305
 - pretransplant cross-match, 289–90
 - sensitisation in, 290
 - UK matching system, 290
 - for ESKD, 277
 - evaluation for, 280–2, 281
 - cardiac disease, 281
 - obesity, 282
 - oral hygiene, 282
 - peptic ulceration, 281–2
 - PKD, 281
 - respiratory disease, 282
 - urinary tract, 281
 - first human-to-human, 14
 - future directions in, 16
 - history of, 13–16
 - the beginning, 13–14
 - blood transfusions, 16
 - current, 16
 - first successes, 14
 - immunosuppression, 14–15
 - immunosuppression for, 317–21 *see also* immunosuppression
 - increasing donor organ supply, 310–13, 311
 - introduction, 277–8, 278
 - keeping transplants safe, 293, 294
 - long-term post-transplant care, 396
 - LRD, 302–10, 304, 306, 307, 308 *see also* living relation donation (LRD)
 - national waiting-list figures for, 278, 278
 - postoperative care, 395–6
 - pretransplant anxieties and fears, 283–4
 - pretransplant preparation, 282–3, 283–5
 - psychological perspectives on, 96–101, 100
 - living kidney donors, 96–101, 100
 - rejection, 321–4, 322, 323 *see also* renal transplant rejection
 - surgical technique for, 315–16, 316, 315
 - US in, 174
 - waiting list for, 285–6
- renal transplant recipients
 - complications in, 326–8 *see also* renal transplantation, complications of
 - dietary advice for, 397
 - discharge from hospital, 329, 329
 - kidney biopsy in, 170–1
 - LRD for
 - benefits of, 303
 - ongoing care for, 330
 - postoperative care for, 324–6
 - aims of care, 324
 - cardiorespiratory status, 324
 - continuing care, 326
 - hydration, 324–5
 - immediate, 324
 - infection control, 325
 - medications, 325–6
 - pain management, 324
 - urine output, 325
 - wound management, 325
 - preoperative management of, 313–15, 313–15
 - immediate preoperative care, 314, 315
 - information and emotional support, 314
 - medical assessment, 314, 314
 - nursing admission procedure, 313, 313
 - preoperative dialysis, 314
 - transplant call, 313
- renal transplant rejection, 321–4, 322, 323
 - ABMR, 322, 323
 - acute rejection, 322, 323, 326
 - CAI, 323–4
 - hyperacute rejection, 321–2, 322
 - transplant biopsy, 322–3
 - types of, 321
- renal tubule
 - histological features of, 30, 31
- renin, 34
- renin–angiotensin–aldosterone pathway, 34–5, 35
- renograms
 - in renal assessment, 174–5
- ResearchGate
 - RPSG on, 73
- respiratory disease
 - in evaluation for renal transplantation, 282
- restless legs syndrome
 - end-of-life care related to, 345
- reticulocytes
 - in renal profile, 161–2
- retrograde pyelogram
 - in renal assessment, 173
- rhabdomyolysis
 - AKI related to, 110
- Richardson, B.W., 2
- RIFLE, 112, 112
- Robertson, L.M., 373, 374
- Robinski, M., 86
- Romans
 - in dialysis history, 1–2
- rope ladder technique
 - in AVF and AVG function preservation, 214, 215–16, 216
- Rosenak, S., 10
- Royal College of Physicians, 397
- Royal Free Hospital, 6
- RPSG. *see* Renal Patient Support Group (RPSG)
- RPSG Admin/Research team, 72
- RRT. *see* renal replacement therapy (RRT)
- RRTOE. *see* renal replacement therapy option education (RRTOE)
- Ruben, R., 10
- Rylance, P.B., 220
- Sadeghian, J., 92
- safety
 - patient-related, 414–18, 415, 417, 418 *see also* patient safety
- Sargent, J.A., 258
- Saunders, Dame C., 336
- scleroderma
 - renal effects of, 57
- sclerosis(es)
 - encapsulating peritoneal, 261
 - systemic
 - renal effects of, 57

- Scribner, B., 6, 8, 11
secretion, 31
Selby, N.M., 203
selective reabsorption, 29–31, 31
self-care
 psychological perspectives on, 94–5, 95
self-confidence
 experience of, 99
self-management
 of stage 3a–3b CKD, 133–4
sensitisation
 in donor and recipient
 matching for renal transplantation, 290
sepsis
 AKI-related
 management of, 116–17
serological tests
 in renal profile, 156
serum bicarbonate
 in stage 4 CKD
 control of, 136–7
serum iron
 in renal profile, 160
serum protein electrophoresis
 in renal profile, 155
Servelle, 14
Seven-Point Subjective Global Assessment, 406
sexual function
 stage 4 CKD effects on, 140
sexuality
 psychological perspectives on, 91–3, 91
SGA. *see* Subjective Global Assessment (SGA)
Shaldon, S., 6
SHARED-HD, 95, 192
sharp(s)
 Health and Safety Executive (Sharps Instruments in Healthcare) Regulations on, 148
Sharples, E., 374
shoulder pain
 PD and, 264
Simmonds, R., 131
simultaneous pancreas-kidney (SPK) transplant, 330–1
single-needle *vs.* double-needle dialysis
 in improving HD clearance, 198
sirolimus
 in maintenance
 immunosuppression, 320–1
Skeggs, L., 5
skeletal x-rays
 in renal assessment, 171–2
SLE. *see* systemic lupus erythematosus (SLE)
sleep disturbance
 end-of-life care related to, 345
Smart, N.A., 84
social issues
 in palliative care, 345–6
social media
 background on, 70–1
 patient involvement in renal nursing care using, 70–4
sodium
 foods with high and low content of, 407
 in HD prescription, 192, 193–4, 193
 in renal profile, 151, 152
 requirements in dialysis patients, 383–4, 383
sodium sieving
 in PD, 262
solution formulation
 for PD, 254–7, 254, 257 *see also* peritoneal dialysis (PD), solution formulation
SONG. *see* Standardised Outcomes in Nephrology (SONG)
SPA. *see* standardised peritoneal assessment (SPA)
Specialist Nurse for Organ Donation (SNOD), 293, 294
 role in deceased donation, 297, 298
special needs
 PD for
 advances in, 13
spiritual care, 346
spirituality
 in end-of-life care, 346
SPK transplant. *see* simultaneous pancreas-kidney (SPK) transplant
SSNS. *see* steroid sensitive nephrotic syndrome (SSNS)
Staley, K., 76
Standardised Outcomes in Nephrology (SONG), 93–4, 226
standardised peritoneal assessment (SPA), 240
Staphylococcus aureus
 screening for
 prior to PD, 244
Steddon, S., 374
Steiber, A.L., 380
stenosis(es)
 renal artery
 CKD due to, 43–5, 44, 45
steroid sensitive nephrotic syndrome (SSNS), 355
Stevens, P., 132
Stewart, G., 85
Stewart, R., 6
Strand, H., 94
Strategy for Living Donor Kidney Transplantation, 305
Subjective Global Assessment (SGA), 378
 in body composition assessment, 391
 Seven-Point, 406
success
 defined, 421
Swan-neck catheter
 in PD, 243, 243
systemic lupus erythematosus (SLE)
 renal effects of, 56
systemic sclerosis
 renal effects of, 57
tacrolimus (FK506)
 in maintenance
 immunosuppression, 319
“Taking Organ Transplantation to 2020,” 312
Tamm–Horsfall proteins, 165
Taylor, D.M., 85
T-cell depleting antibodies (TDA)
 in immunosuppression induction, 318
TCVCs. *see* tunnelled central venous catheters (TCVCs) care
TDA. *see* T-cell depleting antibodies (TDA)
team communication
 in palliative care, 340
Tenckhoff catheter, 11–12
 in PD, 243, 244, 243
Tenckhoff, H., 11
Terasaki, P.I., 16
Teschner, P., 4, 7
Thalhimer, W., 3
“The KDIGO Controversies Conference on Supportive Care in CKD,” 338
therapeutic plasma exchange (TPE)
 in AKI, 122
thirst
 mechanism of, 34
thrombocytopenia
 heparin-induced
 HD and, 206–7
thrombosis
 of renal artery or vein
 after renal transplantation, 326
tidal peritoneal dialysis (TPD), 250, 250
tiredness
 NS and, 48
tissue-type inheritance, 305, 306
Titus, T.T., 84
Toronto Western catheter
 in PD, 243, 243
Toronto Western Hospital, 11

- total protein-creatinine ratio (TPCR), 167
- TPCKD programme. *see* Transforming Participation in Chronic Kidney Disease (TPCKD) programme
- TPCR. *see* total protein-creatinine ratio (TPCR)
- TPD. *see* tidal peritoneal dialysis (TPD)
- TPE. *see* therapeutic plasma exchange (TPE)
- transferrin saturation rate in renal profile, 160
- Transforming Participation in Chronic Kidney Disease (TPCKD) programme, 226
- transplant antigen, 286
- transplantation
- kidney *see* renal transplantation
 - living donor
 - for children, 356–7
 - pancreas-kidney, 330–2, 331
 - pancreatic, 330–2, 331
 - pre-emptive
 - for children, 357
- transplantation waiting list, 285–6
- transplant biopsy, 322–3
- transplant call, 313
- transplant patients. *see* renal transplant recipients
- transplant renal artery stenosis after renal transplantation, 327
- Treadwell, A., 90
- Tsujimoto, Y., 204
- tubing kinks in PD, 263
- Tu, H.-Y., 87
- tunnel infection PD and, 269–70
- tunnelled central venous catheters (TCVCs) care, 208, 210, 218–19
- flow problems prevention in, 219
 - in infection prevention, 218–19
- Twardowski, Z.J., 214, 240
- Twitter RPSG on, 71
- UF. *see* ultrafiltration (UF)
- UFR. *see* ultrafiltration rate (UFR)
- UK Code of Practice, 292
- UK Department of Health, 81
- UK Donation Ethics Committee, 301
- UK matching system in donor and recipient matching for renal transplantation, 290
- UKPDS. *see* UK Prospective Diabetes Study (UKPDS)
- UK Prospective Diabetes Study (UKPDS), 373
- UK Renal Registry. *see* Renal Registry
- ulcer(s)
- peptic in evaluation for renal transplantation, 281–2
- ultrafiltration (UF) in HD, 186, 187, 187
- osmotic during PD, 239–40
- ultrafiltration rate (UFR) management of in HD prescription, 202–3
- ultra-pure water in HD prescription, 192, 193, 194
- ultrasound (US) in AKI detection, 113
- in renal assessment, 173–4
 - in renal transplantation, 174
- unfractionated heparin in anticoagulation, 204–7, 207
- in clotting management in HD *vs.* LMWH, 206, 207
- University of Colorado, 15
- University of Hertfordshire, 60
- University of Minnesota, 13
- University of Washington Hospital, 6, 11
- uraemia
- AKI-related management of, 115
- urea in PD adequacy assessment, 258, 259
- in renal profile, 151–2, 151
- urea rebound, 196
- urea reduction ratio (URR) in HD clearance, 195–6, 196
- measurement of, 195–6, 196
- uric acid in renal profile, 154
- urinalysis in AKI detection, 113
- described, 162
 - in renal profile, 162–5, 162 *see also* urine
- urinary concentration countercurrent mechanisms of, 32
- kidneys in, 25–6, 26
- urinary content kidneys in, 27
- urinary tract in evaluation for renal transplantation, 281
- urinary tract infections (UTIs) PKD and, 55
- urinary volume kidneys in, 24–5, 26
- urine
- albumin in, 164
 - appearance of, 162–3
 - Bence Jones protein in, 164
 - blood in, 163
 - casts in, 165
 - components of, 162
 - concentration and dilution of, 32
 - glucose in, 163
 - microalbuminuria, 164
 - microscopy and culture of, 165
 - myoglobin in, 165
 - normal volume of, 162, 162
 - osmolality of, 163
 - protein in, 163–4
 - in renal profile, 162–5, 162
 - urine investigations, 162–5, 162 *see also specific types*
 - versatility of kidneys in, 23–4
- urine concentration renal processes in, 32
- urine output in postoperative care of renal transplant recipients, 325
- types of, 117
- urological obstruction AKI-related management of, 114
- URR. *see* urea reduction ratio (URR)
- US. *see* ultrasound (US)
- UTIs. *see* urinary tract infections (UTIs)
- van der Sande, F.M., 203–4
- varicella zoster virus (VZV) after renal transplantation, 328
- vascular access for HD, 183–4, 207–20 *see also* haemodialysis (HD), vascular access for in children, 360
- types of, 184
- vascular access recirculation in improving HD clearance, 197–8
- vasopressin, 26
- venesection sites for, 149, 149
- venous needle dislodgement (VND) during HD, 223, 224
- very low-protein diet (VLPD), 367–8
- viral infections after renal transplantation, 327–8
- viral serology in renal profile, 156
- Visser, R., 379
- vitamin(s) for ERF patients, 386, 386
- requirements for in dialysis patients, 383, 385–6, 386
 - nutritional, 380

- vitamin B₁₂
 - in renal profile, 160
- vitamin D
 - “active,” 374
 - metabolism of
 - dietary management of, 374
 - in phosphate and calcium control, 37–8, 38, 39
- VLPD. *see* very low-protein diet (VLPD)
- VND. *see* venous needle dislodgement (VND)
- volume disorders
 - in stage 4 CKD
 - control of, 138–9
- volume overload
 - AKI-related
 - management of, 115
- vomiting
 - end-of-life care related to, 344
- Voronoy, 14
- VZV. *see* varicella zoster virus (VZV)
- Wadd, K., 87
- waiting list
 - for renal transplantation, 285–6
- Walter, C., 4
- warm ischaemia
 - in deceased donation, 300
- Warrick, C., 9
- Warwick, G., 94
- water
 - ultra-pure
 - in HD prescription, 192, 193, 194
- WBC. *see* white blood cell (WBC)
- weight loss
 - nephrotic syndrome and, 48
- wellbeing
 - in PD adequacy assessment, 258, 260
 - physical, 302
 - psychological, 302
- white blood cell(s) (WBCs), 286
- white blood cell (WBC) count and differential
 - in renal profile, 157, 158–60
- WHO. *see* World Health Organisation (WHO)
- Wiederhold, D., 99
- Williams, L.A., 90
- World Health Organisation (WHO)
 - “analgesic ladder” of, 344
 - on palliative care, 336, 337
 - on phlebotomy, 148
- World Kidney Day 2018, 140
- worry(ies)
 - experience of, 99
- wound management
 - in postoperative care of renal transplant recipients, 325
- Wren, Sir C., 7
- Wright, M., 379
- x-rays
 - plain abdominal
 - in renal assessment, 171
 - skeletal
 - in renal assessment, 171–2
- young adults
 - renal care of, 349–66
- Y-system (flush before fill), 12
- Zeraati, A., 197